Target intelligence / Profile preview

Class C and Class D beta-lactamases (OXA and ADC subtypes) (OXA and ADC beta-lactamases)

Target
OXA and ADC beta-lactamases
Molecular classification
Enzyme, Serine hydrolase, Beta-lactamase
01

Overview

Class C and Class D beta-lactamases, specifically the Acinetobacter-derived cephalosporinases (ADC) and oxacillinases (OXA), are critical enzymes that mediate antibiotic resistance in Gram-negative bacteria such as Acinetobacter baumannii (PubMed: 25246706). These enzymes function by hydrolyzing the beta-lactam ring of various antibiotics, including cephalosporins and carbapenems, thereby neutralizing their bactericidal effects (PubMed: 28196865). The OXA family is particularly diverse, with many variants functioning as carbapenem-hydrolyzing class D beta-lactamases (CHDLs), which are a leading cause of carbapenem resistance globally (PubMed: 24277854). ADC enzymes are chromosomally encoded cephalosporinases that, when overexpressed due to genetic insertion sequences, confer high-level resistance to extended-spectrum cephalosporins (PubMed: 16148278). Therapeutic strategies targeting these enzymes involve the use of beta-lactamase inhibitors like durlobactam, which are often paired with beta-lactams like sulbactam (FDA: Xacduro Label). These inhibitors work by forming a stable, covalent complex with the active-site serine of the enzyme, preventing it from degrading the antibiotic and restoring the drug's efficacy against multidrug-resistant pathogens (PubMed: 33851814).

Other names
OxacillinasesAcinetobacter-derived cephalosporinasesClass D serine beta-lactamasesClass C serine beta-lactamasesCarbapenem-hydrolyzing class D beta-lactamases (CHDLs)AmpC-type beta-lactamases
02

Mechanism of action

Covalent inhibition of the active-site serine residue within the beta-lactamase enzyme, preventing the hydrolysis of beta-lactam antibiotics.

03

Biological functions

Antibiotic hydrolysisBacterial defense mechanismPeptidoglycan metabolism interference
04

Disease associations

Bacterial infectionAntimicrobial resistanceHospital-acquired pneumoniaVentilator-associated pneumoniaSepsis
05

Safety considerations

Emergence of inhibitor-resistant variants through point mutationsNarrow spectrum of activity for some inhibitors against specific Class D variantsPotential for co-resistance with other antibiotic classes
06

Interacting drugs

Durlobactam

6 more in the full profile.

07

Biomarkers

blaOXA-23blaOXA-24/40blaOXA-51blaOXA-58blaADC genesCarbapenem-resistant Acinetobacter baumannii (CRAB) status

Beyond the preview

Go deeper on Class C and Class D beta-lactamases (OXA and ADC subtypes) (OXA and ADC beta-lactamases).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Class C and Class D beta-lactamases (OXA and ADC subtypes) (OXA and ADC beta-lactamases).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call